Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Anti SLAMF7 chimeric antigen receptor T cell therapy - T-Curx

Next Previous
X
Search
Drug Profile

Anti SLAMF7 chimeric antigen receptor T cell therapy - T-Curx

Latest Information Update: 30 Aug 2023

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University Hospital of Wurzburg
  • Developer T-CURX; University Hospital of Wurzburg
  • Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Multiple myeloma
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Multiple myeloma

Most Recent Events

  • 22 Jul 2022 Phase-I/II clinical trials in Multiple myeloma (Second-line therapy or greater) in France (IV) (NCT04499339)
  • 09 Sep 2020 T-CURX in-licenses CAR-T cell technology and patents from University of Wurzburg
  • 22 Jun 2020 Phase-I/II clinical trials in Multiple myeloma (Second-line therapy or greater) in Italy (IV) (EudraCT2019-001264-30)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top